Search Results for "montelukast"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for montelukast. Results 1 to 5 of 5 total matches.
See also: Singulair

In Brief: Neuropsychiatric Events with Montelukast

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
In Brief: Neuropsychiatric Events with Montelukast ...
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast (Singulair, and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Med Lett Drugs Ther. 2020 May 4;62(1597):65 |  Show IntroductionHide Introduction

Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
, and generics), and montelukast (Singulair, and generics) have been used (off-label) in patients ...
Difelikefalin (Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults on hemodialysis. It is the first drug to be approved for this indication and the first KOR agonist to become available in the US. Difelikefalin has not been studied in patients on peritoneal dialysis.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):18-9 |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
receptor antagonists (LTRAs) montelukast and zafirlukast are alternatives for patients who are unable ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
has been associated with small decreases in growth velocity.12 MONTELUKAST — The oral leukotriene receptor ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
Pediatric Dosage Adverse Effects Class Comments Cost2 Leukotriene Receptor Antagonist Montelukast ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e55-7   doi:10.58347/tml.2025.1725b |  Show IntroductionHide Introduction